Alzheimer’s Breakthrough Meets The Budget Wall

Send us Fan MailA medical breakthrough can still fail at the pharmacy counter. We finally have amyloid-targeting drugs for early-stage Alzheimer’s disease, and they are already on the market, but several major health systems have looked at the same evidence and refused to pay. That contradiction is the mystery we unpack, using the explosive Glasgow IPCAD meeting as our guide to what’s really blocking access.We dig into the three barriers driving negative reimbursement decisions: headline drug prices, serious safety risks that require ongoing MRI monitoring, and the hardest problem of all, long-term efficacy. When trials last about 18 months, payers are forced to guess whether small changes in cognitive scores translate into years of real independence. From there, we explore the new toolkit health economists are building, including AI-supported micro-simulation models that create thousands of virtual patients and project outcomes decades into the future.The conversation turns practical fast. We explain why caregiver burden and caregiver quality of life can change the math, why biomarker diagnostics like PET scans and lumbar punctures can bankrupt a system before the first dose, and how real-world evidence programs like coverage with evidence development try to balance access with learning. We also look at global registry efforts such as INRAD that standardize data across borders, then confront the uncomfortable truth: even if the money shows up, many countries lack the infusion clinics, diagnostic capacity, and specialist workforce to deliver these therapies at scale.We close with a provocative question about the near future of blood-based screening and presymptomatic diagnosis, and what it means to know you’re at risk while treatment remains financially out of reach. If this helped you think differently about Alzheimer’s policy, health economics, and brain health, subscribe, share the episode, and leave a review so more people can find it.This podcast is created by Ai for educational and entertainment purposes only and does not constitute professional medical or health advice. Please talk to your healthcare team for medical advice. Never miss an episode—subscribe on your favorite podcast app!